Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin With or Without PD-1 Inhibitor in Advanced ESCC
NCT07403136Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Started Apr 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07403136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403136.